Hearn Jay Cho, MD, explains how immune profiling could inform what impairs T-cell fitness, a crucial consideration when using CAR T-cell therapy or bispecific T-cell engagers.
Hearn Jay Cho, MD, PhD
Advertisement
Hearn Jay Cho, MD, PhD, is an associate professor of medicine (hematology and medical oncology) at the Icahn School of Medicine at Mount Sinai.
Articles by Hearn Jay Cho, MD, PhD
Hearn Jay Cho, MD, PhD, discusses the ongoing role of the CoMMpass dataset in researching immunotherapy and targeted therapy in high-risk multiple myeloma.
Hearn Jay Cho, MD, PhD, of the Multiple Myeloma Research Foundation, looks back on 15 years of the groundbreaking CoMMpass genomic study.
Hearn Jay Cho, MD, PhD, discusses the goals of the CureCloud study, an historic initiative of the Multiple Myeloma Research Foundation (MMRF), a leader in the acceleration of efforts to provide precisely the right treatment for each and every patient.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM
2
Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices
3
FDA Application Withdrawn for I-DXd in Small Cell Lung Cancer
4
Frontline CAR T and Bispecific Antibodies Are the Next Frontier in Myeloma
5